Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ODC1 | P11926 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416683 | 1.00 | ALDH1A1 (0.37) | ALDH1A1TSHRHTTMEN1CYP1A2 | |
| SCHEMBL1416684 | 1.00 | ALDH1A1 (0.37) | ALDH1A1TSHRHTTMEN1CYP1A2 | |
| Hydrogen Sulfide SCHEMBL27650551 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TSHRHTTMEN1CYP1A2 | |
| SCHEMBL27514629 | 0.96 | ALDH1A1 (0.35) | ALDH1A1TSHRHTTMEN1CYP1A2 | |
| SCHEMBL30651 | 0.86 | ALDH1A1 (0.42) | ALDH1A1TSHRHTTMEN1CYP1A2 | |
| SCHEMBL3852636 | 0.83 | HTT (0.39) | ALDH1A1TSHRHTT | |
| SCHEMBL3853291 | 0.83 | HTT (0.39) | ALDH1A1TSHRHTT | |
| SCHEMBL3852641 | 0.83 | HTT (0.39) | ALDH1A1TSHRHTT | |
| SCHEMBL30787966 | 0.80 | ARG2 (0.41) | ALDH1A1TSHRHTTMEN1CYP1A2 | |
| SCHEMBL11087825 | 0.78 | ODC1 (0.48) | ALDH1A1TSHRHTTMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686114-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKYLCYSTEINE, DERIVATIVE THEREOF, AND PROCESSES FOR PRODUCTION | MITSUBISHI GAS CHEMICAL CO (JP) | 2009-10-07 | — | — | EP | claimed |
| US-20090030210-A1 | Process for Producing Optically Active 2-Alkylcysteine, Derivative Thereof, and Processes for Production | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-01-29 | — | — | US | claimed |
| US-7470525-B2 | Process for producing optically active 2-alkycysteine, derivative thereof, and processes for production | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-12-30 | — | — | US | claimed |
| US-20070037260-A1 | allowing cells of microorganism or treated products thereof having an activity of stereoselective hydrolysis of the amide bond of a 2-alkyl-L-cysteinamide or a salt thereof to act on a 2-alkylcysteinamide consisting of a mixture of D- and L-isomers or a salt thereof | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2007-02-15 | — | — | US | claimed |
| EP-1686114-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKYLCYSTEINE, DERIVATIVE THEREOF, AND PROCESSES FOR PRODUCTION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2006-08-02 | — | — | EP | claimed |
| EP-1686114-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKYLCYSTEINE, DERIVATIVE THEREOF, AND PROCESSES FOR PRODUCTION | MITSUBISHI GAS CHEMICAL CO (JP) | 2009-10-07 | — | — | EP | disclosed |
| EP-1686114-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKYLCYSTEINE, DERIVATIVE THEREOF, AND PROCESSES FOR PRODUCTION | MITSUBISHI GAS CHEMICAL CO (JP) | 2009-10-07 | — | — | EP | disclosed |
| EP-1529037-B1 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090030210-A1 | Process for Producing Optically Active 2-Alkylcysteine, Derivative Thereof, and Processes for Production | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090030210-A1 | Process for Producing Optically Active 2-Alkylcysteine, Derivative Thereof, and Processes for Production | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-7470525-B2 | Process for producing optically active 2-alkycysteine, derivative thereof, and processes for production | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-12-30 | — | — | US | disclosed |
| US-7470525-B2 | Process for producing optically active 2-alkycysteine, derivative thereof, and processes for production | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-12-30 | — | — | US | disclosed |
| US-6878828-B2 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | GENZYME CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| US-6861532-B2 | Synthesis of 2-alkylcysteine | GENZYME CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6794515-B2 | CONDENSING CYSTEINE WITH CABOCYCLIC NITRILES TO FORM 2-ARYLTHIAZOLINE-4-CARBOXYLIC ACID, THEN AMIDATION, ALKYLATION, HYDROLYZING AND OPTIONALLY PURIFYING TO FORM 2-METHYLCYSTEINE | GENZYME CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | GENZYME CORPORATION (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | GENZYME CORPORATION | 2003-12-11 | — | — | US | disclosed |
| WO-2003097622-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | ALDH1A1 2230/4885TSHR 1787/4885HTT 297/4885 |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | FTH1, TFRC, CNDP2 | ALDH1A1 751/4885TSHR 178/4885HTT 562/4885 |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | FTH1, CISD2, CNDP2 | ALDH1A1 3782/4885TSHR 499/4885HTT 208/4885 |
| US-20090030210-A1 | Process for Producing Optically Active 2-Alkylcysteine, Derivative Thereof, and Processes for Production | AADAT, CBS, CTH | ALDH1A1 444/4885TSHR 4348/4885HTT 1136/4885 |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | CNDP2, FTH1, PTMS | ALDH1A1 2802/4885TSHR 485/4885HTT 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.